Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: To report an anatomic change observed in a series of patients who underwent subretinal injection of voretigene neparvovec-rzyl (VN) for RPE65-mediated Leber congenital amaurosis. Design: Multi-center retrospective chart review. Participants: Patients who underwent subretinal VN injection at each of four participating institutions. Methods: Patients were identified as having perifoveal chorioretinal atrophy if: i) the areas of atrophy were not directly related to the touch-down site of the subretinal cannula; and ii) the area of atrophy progressively enlarged over time. Demographic data, visual acuity, refractive error, fundus photos, optical coherence tomography, visual fields, and full-field stimulus threshold (FST) were analyzed. Main Outcome Measures: Outcome measures included change in visual acuity, FST, visual fields, and location of atrophy relative to subretinal bleb position. Results: 18 eyes of 10 patients who underwent subretinal injection of VN were identified as having developed perifoveal chorioretinal atrophy. 8/10 patients (80%) developed bilateral atrophy. The mean age was 11.6 years (range: 5–20), and 6 patients (60%) were male. Baseline mean logMAR visual acuity and FST were 0.82 (standard deviation (SD): 0.51) and −1.3 log cd.s/m2(SD: 0.44), respectively. The mean spherical equivalent was −5.7 diopters (range: 11.50 to +1.75). Atrophy was identifiable at an average of 4.7 months (SD: 4.3) following surgery, and progressively enlarged in all cases up to a mean follow-up period of 11.3 months (range: 4–18). Atrophy developed within and outside the area of the subretinal bleb in 10 (55.5%) eyes, exclusively within the area of the bleb in 7 (38.9%) eyes, and exclusively outside the bleb in 1 (5.5%) eye. There was no significant change in visual acuity (p=0.45). There was a consistent improvement in FST with a mean improvement of −3.21 log cd.s/m2(p<0.0001). Additionally, all 13 eyes with reliable pre- and post-operative Goldmann visual fields demonstrated improvement (expansion and/or gain of isopters) following surgery, but 3 (23.1%) eyes demonstrated paracentral scotomas related to the atrophy. Conclusions: A subset of patients undergoing subretinal VN injection developed progressive perifoveal chorioretinal atrophy following surgery. Further study is necessary to determine what ocular, surgical delivery, and vector-related factors predispose to this complication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Cited by
Campochiaro, P. A., Avery, R., Brown, D. M., Heier, J. S., Ho, A. C., Huddleston, S. M., Jaffe, G. J., Khanani, A. M., Pakola, S., Pieramici, D. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00310-6 · Cited by 135
Subretinal injection techniques for retinal disease: A review
Irigoyen, C., Amenabar Alonso, A., Sanchez-Molina, J., Rodríguez-Hidalgo, M., Lara-López, A., & Ruiz-Ederra, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164717 · Cited by 106
“To better understand how the risk of this event is influenced by ocular, surgical delivery, and vector-related variables, more research is required [86].”
BackgroundFischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., et al. (2024) · Biomolecules · doi:10.3390/biom14010122 · Cited by 70
Gene therapy for inherited retinal disease: Long-term durability of effect
Leroy, B. P., Fischer, M. D., Flannery, J. G., MacLaren, R. E., Dalkara, D., Scholl, H. P. N., Chung, D. C., Spera, C., Viriato, D., & Banhazi, J. (2023) · Ophthalmic Research · doi:10.1159/000526317 · Cited by 70
Therapy with voretigene neparvovec. How to measure success?
Stingl, K., Kempf, M., Jung, R., Kortüm, F., Righetti, G., Reith, M., Dimopoulos, S., Ott, S., Kohl, S., & Stingl, K. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101115 · Cited by 48
Kessel, L., Christensen, U. C., & Klemp, K. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.06.018 · Cited by 46
Syndromic retinitis pigmentosa.
Karuntu, J. S., Almushattat, H., Nguyen, X.-T.-A., Plomp, A. S., Wanders, R. J. A., Hoyng, C. B., van Schooneveld, M. J., Schalij-Delfos, N. E., Brands, M. M., Leroy, B. P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101324 · Cited by 39
Wiley, L. A., Boyce, T. M., Meyering, E. E., Ochoa, D., Sheehan, K. M., Stone, E. M., Mullins, R. F., Tucker, B. A., & Han, I. C. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.222 · Cited by 30
“10, AAV-mediated inflammation is an important consideration when development approaches for human gene therapy.”
Injection pressure levels for creating blebs during subretinal gene therapy
Scruggs, B. A., Vasconcelos, H. M., Matioli da Palma, M., Kogachi, K., Pennesi, M. E., Yang, P., Bailey, S. T., & Lauer, A. K. (2022) · Gene Therapy · doi:10.1038/s41434-021-00294-2 · Cited by 28
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
Kovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20
Seitz, I. P., Wozar, F., Ochakovski, G. A., Reichel, F. F., Gelisken, F., Bartz-Schmidt, K. U., Peters, T., & Fischer, M. D. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100516 · Cited by 16
“3,13 Increased injection pressures have been known to cause atrophy at the injection site in both monkeys 14 and pigs.”
BackgroundFeasibility of direct vitrectomy-sparing subretinal injection for gene delivery in large animals
Stranak, Z., Ardan, T., Nemesh, Y., Toms, M., Toualbi, L., Harbottle, R., Ellederova, Z., Lytvynchuk, L., Petrovski, G., Motlik, J., et al. (2024) · Current Eye Research · doi:10.1080/02713683.2024.2343335 · Cited by 7
“9,10 Many aspects of retinal gene therapy safety were initially overlooked such as inflammatory side effects arising from the AAV capsid or its transgene, but this may also be increased or promoted by the injection routes and the surgical procedure.”
Metadata
- Authors
- Gange, W. S., Sisk, R. A., Besirli, C. G., Lee, T. C., Havunjian, M., Schwartz, H., Borchert, M., Sengillo, J. D., Mendoza, C., Berrocal, A. M., & Nagiel, A.
- Venue
- Ophthalmology Retina
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 6
- Issue
- 1
- Pages
- 58-64
- ISSN
- 2468-6530 (ISSN-L)
- OpenAlex
- W3148863837
- Cited by
- 156
- References
- 4
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.